Table 5 External validation of immune response prognostic module: distribution of poor and good outcome patients in over-and-underexpressed subgroups
Gene | Â | UPP | JRH-2 | Combined | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Poor | Good | P | Poor | Good | P | Poor | Good | P |
IGLC2 | High | 0 | 12 | 0.04 | 0 | 7 | 0.09 | 0 | 19 | 0.003 |
| Â | Low | 6 | 13 | Â | 6 | 11 | Â | 12 | 24 | Â |
LY9 | High | 1 | 16 | 0.05 | 0 | 6 | 0.14 | 1 | 22 | 0.007 |
| Â | Low | 5 | 9 | Â | 6 | 12 | Â | 11 | 21 | Â |
TNFRSF17 | High | 1 | 16 | 0.05 | 0 | 10 | 0.02 | 1 | 26 | 0.001 |
| Â | Low | 5 | 9 | Â | 6 | 8 | Â | 11 | 17 | Â |
C1QA | High | 0 | 12 | 0.04 | 0 | 9 | 0.04 | 0 | 21 | 0.001 |
| Â | Low | 6 | 13 | Â | 6 | 9 | Â | 12 | 22 | Â |